	US 12,274,699 B2
	Methods of treating cholangiocarcinoma
Siraj Mahamed Ali, Cambridge, MA (US); Matthew J. Hawryluk, Newton, MA (US); Jie He, Newton, MA (US); Doron Lipson, Chestnut Hill, MA (US); Vincent A. Miller, West Orange, NJ (US); Jeffrey S. Ross, Lebanon Springs, NY (US); and Philip James Stephens, Lexington, MA (US)
Assigned to Foundation Medicine, Inc., Boston, MA (US)
Filed by Foundation Medicine, Inc., Cambridge, MA (US)
Filed on Jun. 30, 2023, as Appl. No. 18/346,029.
Application 17/204,830 is a division of application No. 14/761,518, granted, now 10,980,804, issued on Apr. 20, 2021, previously published as PCT/US2014/012136, filed on Jan. 17, 2014.
Application 18/346,029 is a continuation of application No. 17/204,830, filed on Mar. 17, 2021, granted, now 11,771,698.
Claims priority of provisional application 61/756,372, filed on Jan. 24, 2013.
Claims priority of provisional application 61/754,509, filed on Jan. 18, 2013.
Prior Publication US 2023/0372338 A1, Nov. 23, 2023
Int. Cl. A61K 31/517 (2006.01); A61K 31/19 (2006.01); A61K 31/404 (2006.01); A61K 31/435 (2006.01); A61K 31/4412 (2006.01); A61K 31/4439 (2006.01); A61K 31/47 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/53 (2006.01); A61K 31/5383 (2006.01); A61K 31/553 (2006.01); A61K 45/06 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 16/40 (2006.01); C12N 9/12 (2006.01); C12N 15/113 (2010.01); C12Q 1/6883 (2018.01); C12Q 1/6886 (2018.01); G01N 33/573 (2006.01)

CPC A61K 31/5025 (2013.01) [A61K 31/404 (2013.01); A61K 31/435 (2013.01); A61K 31/4412 (2013.01); A61K 31/4439 (2013.01); A61K 31/47 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/53 (2013.01); A61K 31/5383 (2013.01); A61K 31/553 (2013.01); A61K 45/06 (2013.01); C07K 14/705 (2013.01); C07K 14/71 (2013.01); C07K 16/40 (2013.01); C12N 9/12 (2013.01); C12N 15/1137 (2013.01); C12Q 1/6883 (2013.01); C12Q 1/6886 (2013.01); C12Y 207/10001 (2013.01); G01N 33/573 (2013.01); C07K 2319/00 (2013.01); C12N 2310/11 (2013.01); C12N 2310/12 (2013.01); C12N 2310/14 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/912 (2013.01); G01N 2500/04 (2013.01)]

24 Claims

1. A method of determining presence of a fibroblast growth factor receptor (FGFR) gene fusion or a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, comprising:

detecting an FGFR or NTRK gene fusion in an FGFR or NTRK nucleic acid molecule or polypeptide in a sample obtained from a subject that has or is at risk of having a cholangiocarcinoma, thereby determining that the FGFR or NTRK gene fusion is present in the sample; and

responsive to the determination of the presence of the FGFR or NTRK gene fusion in the sample, generating a report comprising one or more therapeutic options comprising a therapeutic agent that antagonizes or inhibits an FGFR gene or gene product or an NTRK gene or gene product.